Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.’s share was trading at $8.33 as of June 9th. BCRX’s trailing and forward P/E were 7.46 and 72.99 respectively according to Yahoo Finance.
Copyright: dolgachov / 123RF Stock Photo
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BCRX is rated Bullish with a $22.00 target implying +140% upside as it evolves into a diversified rare disease leader in hereditary angioedema (HAE) across oral and injectable modalities.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The market is mispricing the combined ORLADEYO and navenibart franchise by viewing oral and injectable therapies as substitutes rather than complementary, creating a clear sum-of-the-parts opportunity. ORLADEYO anchors the business with $600M+ in recurring revenue, 21% growth, and APeX-S data demonstrating a 91% reduction in attack rates alongside a strong safety profile. Navenibart adds a differentiated twice-yearly injectable showing a 92% reduction in Phase 1b, expanding full-spectrum HAE coverage and reducing patient churn to competitors.
This dual-modality strategy is reinforced by orphan drug exclusivity, ORLADEYO patent protection through 2035, and the integration of biologics capabilities via the Astria acquisition. Near-term catalysts include BCX17725 Netherton syndrome Phase 1 Part 4 data in late 2026 and continued advancement of navenibart toward Phase 3 readouts and a 2027 BLA submission. Financial performance remains stable with Q1 2026 revenue of $156.4 million, full-year guidance of $625–$645 million, and a $160 million cash position strengthened by prior debt reduction.
The bull case assumes ORLADEYO reaches $1.1 billion in peak sales and navenibart contributes $650 million, supporting a re-rating toward $32–$35 per share. The bear case implies ~$5 per share if competitive pressure accelerates and growth decelerates. Overall, BioCryst presents a high-conviction bullish re-rating opportunity driven by durable rare disease demand, expanding pipeline optionality, strong clinical validation, and multiple catalysts extending through 2027.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy-driven gene editing commercialization and pipeline optionality across oncology and in vivo editing. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. BioEquity Watch’s Substack shares a similar view but emphasizes BioCryst Pharmaceuticals (BCRX)’s rare disease HAE re-rating and dual-modality franchise expansion.